Treating individuals based on specific health markers, rather than population averages, is crucial because plaque formation can vary significantly even among individuals with similar ApoB levels.

“I treat the individual sitting in front of me I'm not doing population-based medicine you know if you take all comers with you know in April B of 180 well a good chunk of them are going to have you know plaque in their left interior descending and some of them won't yeah which ones won't well you got to know who you know is likely not do they don't have inflammation they don't have insulin resistance they make nitric oxide on demand you know they have healthy endothelial calyx those LL particles are just zipping”